Request Trial
20 December 2016Americas

Editas takes licence to CRISPR technology amid patent battle

Editas Medicine, a US genome-editing company, has taken a licence to intellectual property relating to CRISPR technologies for human therapeutics, amid a continuing CRISPR patent battle.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Eli Lilly escapes $278m payout in biotech licensing dispute
26 February 2026   In a decision with implications for biotechnology licensing and pharmaceutical manufacturing, the Ninth Circuit has rejected a ‘sweeping’ royalty trigger from a lower court.
Americas
Novo battles for GLP-1 leadership with fresh lawsuit and slashed prices
25 February 2026   The Danish company is contending with fierce competition, a clinical trial setback and a UK boost to its main rival, while making new moves to enforce its weight-loss-drug IP.
Americas
BioNTech fires shots at Moderna's next-generation vaccine
20 February 2026   The German biotech claims the newly approved vaccine infringes its mRNA patent, deepening an already complex feud with billions of dollars at stake.


Editor's picks

Eli Lilly escapes $278m payout in biotech licensing dispute
Americas
Eli Lilly escapes $278m payout in biotech licensing dispute
26 February 2026

Editor's picks

Americas
Eli Lilly escapes $278m payout in biotech licensing dispute
26 February 2026
Asia
AstraZeneca partners with Chinese firm ahead of next obesity race
5 February 2026
Americas
The quantum advantage: IP considerations for the next generation of life sciences innovation
27 January 2026
Europe
Final call: Who are the world’s best in-house counsel?
16 January 2026
Americas
Bayer enters COVID-19 vaccine row with three suits against major drugmakers
8 January 2026
Americas
SCOTUS shuts the door on Entresto ‘after-arising technology’ review
17 December 2025

More features

Eli Lilly escapes $278m payout in biotech licensing dispute
Novo battles for GLP-1 leadership with fresh lawsuit and slashed prices
Wiggin’s new litigation partner deepens ‘technically complex’ offer
Could everyday hospital equipment be the next defence against counterfeit medicines?
BioNTech fires shots at Moderna's next-generation vaccine
Mintz gains ex-Winston & Strawn partner and ITC expert
Abbott unit defends European protection for heart valve ‘cuff’ design
Natera targets ex-employee over mass file download before rival move